Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expected to Announce Earnings of -$0.21 Per Share

Wall Street analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report earnings of ($0.21) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Brainstorm Cell Therapeutics’ earnings. The lowest EPS estimate is ($0.24) and the highest is ($0.18). Brainstorm Cell Therapeutics reported earnings of ($0.14) per share in the same quarter last year, which suggests a negative year over year growth rate of 50%. The business is expected to issue its next quarterly earnings report on Thursday, October 21st.

According to Zacks, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.74) per share for the current fiscal year. For the next financial year, analysts forecast that the firm will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.25) to ($0.78). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Thursday, August 5th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.07.

Hedge funds and other institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC bought a new position in shares of Brainstorm Cell Therapeutics in the 1st quarter valued at about $42,000. Advisory Services Network LLC bought a new position in shares of Brainstorm Cell Therapeutics in the 1st quarter valued at about $38,000. HighTower Advisors LLC bought a new position in Brainstorm Cell Therapeutics during the 1st quarter worth approximately $40,000. Price T Rowe Associates Inc. MD boosted its stake in Brainstorm Cell Therapeutics by 460.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 122,161 shares of the biotechnology company’s stock worth $468,000 after acquiring an additional 100,355 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Brainstorm Cell Therapeutics by 17.8% during the 1st quarter. Geode Capital Management LLC now owns 478,258 shares of the biotechnology company’s stock worth $1,831,000 after acquiring an additional 72,335 shares during the last quarter. 15.50% of the stock is currently owned by institutional investors.

Shares of NASDAQ BCLI opened at $3.14 on Friday. The firm has a market capitalization of $114.04 million, a PE ratio of -3.61 and a beta of -0.01. Brainstorm Cell Therapeutics has a 1 year low of $2.92 and a 1 year high of $17.95. The firm’s 50-day moving average is $3.52 and its 200-day moving average is $3.61.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics, Inc operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury.

Recommended Story: What are trading strategies for the 52-week high/low?

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.